These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22058153)

  • 1. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
    Roy R; Krenz M
    J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
    Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
    Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
    PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
    Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
    J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
    Yi JS; Perla S; Enyenihi L; Bennett AM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel, de novo mutation in the
    Xu Y; Gray A; Hardie DG; Uzun A; Shaw S; Padbury J; Phornphutkul C; Tseng YT
    Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H283-H292. PubMed ID: 28550180
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.
    Hahn A; Lauriol J; Thul J; Behnke-Hall K; Logeswaran T; Schänzer A; Böğürcü N; Garvalov BK; Zenker M; Gelb BD; von Gerlach S; Kandolf R; Kontaridis MI; Schranz D
    Am J Med Genet A; 2015 Apr; 167A(4):744-51. PubMed ID: 25708222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
    Cui H; Song L; Zhu C; Zhang C; Tang B; Wang S; Wu G; Zou Y; Huang X; Hui R; Wang S; Wang J
    Orphanet J Rare Dis; 2019 Nov; 14(1):252. PubMed ID: 31722741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
    Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN.
    Xu X; Roe ND; Weiser-Evans MC; Ren J
    Hypertension; 2014 Apr; 63(4):729-39. PubMed ID: 24446058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.
    Dhingra R; Gang H; Wang Y; Biala AK; Aviv Y; Margulets V; Tee A; Kirshenbaum LA
    Circ Heart Fail; 2013 Mar; 6(2):335-43. PubMed ID: 23395931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
    Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
    J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
    Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
    Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.